Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.

ABSTRACT:

Background

Type 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a tyrosine kinase inhibitor that binds to the Abelson tyrosine kinase and related proteins. It enhances β-cell survival in response to toxins and pro-inflammatory cytokine. The aim of this study is to evaluate the effect of imatinib on fasting plasma glucose in subjects with normal fasting glucose, subjects with impaired fasting glucose and in subjects with type 2 diabetes mellitus.

Methods

We identified 284 subjects diagnosed with chronic myeloid leukemia or gastrointestinal stromal tumors f

SUBMITTER: Gomez-Samano MA 

PROVIDER: S-EPMC6215634 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature